APELLIS PHARMACEUTICALS INC. - COMMON STOCK

Apellis Pharmaceuticals Reports First Quarter 2023 Financial Results

04 May 2023 16:05:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Present at the Bank of America Securities 2023 Healthcare Conference

03 May 2023 07:00:01 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Host Conference Call on May 4, 2023, to Discuss First Quarter 2023 Financial Results

27 Apr 2023 07:00:01 By Nasdaq GlobeNewswire

Apellis Presents Phase 3 Functional Analyses of SYFOVRE™ (pegcetacoplan injection) for Geographic Atrophy

23 Apr 2023 18:05:00 By Nasdaq GlobeNewswire

Apellis Announces Validation of Four Marketing Applications for Pegcetacoplan for Geographic Atrophy

21 Apr 2023 07:00:00 By Nasdaq GlobeNewswire

Apellis Partners with Acclaimed Actor Henry Winkler to Raise Awareness of Geographic Atrophy (GA) for the GA Won’t Wait™ Campaign

17 Apr 2023 07:00:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 Apr 2023 16:05:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 Mar 2023 16:05:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

01 Mar 2023 07:00:02 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Option to Purchase Additional Shares

27 Feb 2023 17:19:35 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

22 Feb 2023 21:48:09 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

22 Feb 2023 07:22:35 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results

21 Feb 2023 16:14:10 By Nasdaq GlobeNewswire

FDA Approves SYFOVRE™ (pegcetacoplan injection) as the First and Only Treatment for Geographic Atrophy (GA), a Leading Cause of Blindness

17 Feb 2023 16:06:06 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

13 Feb 2023 16:05:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 Jan 2023 16:05:00 By Nasdaq GlobeNewswire

Apellis Appoints Leading Retina Specialist Dr. Caroline Baumal as Chief Medical Officer

05 Jan 2023 07:00:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference

03 Jan 2023 07:00:00 By Nasdaq GlobeNewswire

Apellis Submits Marketing Authorization Application to the European Medicines Agency for Pegcetacoplan for Geographic Atrophy

16 Dec 2022 07:00:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

07 Dec 2022 16:05:00 By Nasdaq GlobeNewswire